Beijing Indoor Air Purifier Intervention Study

Not Applicable

Completed

• Conditions: Pulmonary Disease
• Interventions: Other: air purifier

• Registration Number: NCT02509000
• Lead Sponsor: WeiHuang

Brief Summary

This study aimed to assess the impact of air filtration on indoor air quality and cardio-pulmonary health in residents living in high outdoor pollution settings in Beijing.

Detailed Description

Not available

Study Timeline

• Study Start: 2013-12
• Primary Completion: 2014-03
• Study Completion: 2014-11
• Status Verified: 2015-07
• Study First Submitted: 2015-07-20
• Study First Submitted QC: 2015-07-23
• Study First Posted: 2015-07-27
• Last Update Submitted: 2015-10-20
• Last Update Posted: 2015-10-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 35

Inclusion Criteria

• Global Initiative for Chronic Obstructive Lung Disease criteria (mild to moderate, GOLD stage I~II;
• severe to very severe, GOLD stage III~IV) quit smoking for at least 1 year;
• a ratio of pre-bronchodilator forced expiratory volume in one second (FEV1) to forced vital capacity (FVC) equal to or less than 0.70 and an increase of FEV1 with the use of 400μg of albuterol of less than 12% of the pre-bronchodilator one;
• no history of asthma or any other active lung disease.
• Subjects were free from exacerbations for at least 6 weeks.

Exclusion Criteria

• Patients with heart pacemaker,
• heart failure with bundle-branch block,
• recent myocardial infarction (in the last 12 weeks) and
• anticoagulant therapy

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Active-mode	air purifier	Air purifier in active-mode
Sham-mode	air purifier	Air purifier in sham-mode

Primary Outcome Measures

Name	Time	Method
respiratory inflammation	4 weeks	analyzed EBC pH and inflammation biomarkers 8-isoprostane and nitrite and nitrate

Secondary Outcome Measures

Name	Time	Method
oxidative stress	4 weeks	analyzed systemic oxidative stress biomarker urinary 8-hydroxy-2-deoxyguanosine (8-OHdG)
systemic inflammation	4 weeks	analyzed systemic inflammation biomarkers C-reaction Protein, Blood coagulation factor fibrinogen (Fib), Interleukin (IL) -8, -1β, -6, -10, -12p70 and tumor necrosis factor-α (TNF-α)